1921
Volume 102, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Public health measures are needed to resolve the novel coronavirus disease (COVID-19) pandemic, although a looming economic fallout merits close attention. Early safe reintroduction of immune individuals into the workforce may be essential to protecting the economic welfare of communities. Reverse transcriptase–polymerase chain reaction testing, our primary diagnostic tool to date, has sensitivity and timing concerns, owing to sampling/handling errors, as well as a complex virus–host interaction. Reverse transcriptase–polymerase chain reaction assays do not establish immune status once the virus has been cleared. Targeted serosurveillance for the determination of individuals’ potential for transmissibility, particularly if paired with direct pathogen testing, may aid in “cleared for business” decision-making.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.20-0302
2020-04-23
2020-11-27
Loading full text...

Full text loading...

/deliver/fulltext/14761645/102/6/tpmd200302.html?itemId=/content/journals/10.4269/ajtmh.20-0302&mimeType=html&fmt=ahah

References

  1. Yu KDS, Aviso KB, 2020. Modelling the economic impact and ripple effects of disease outbreaks. Process Integr Optim Sustain. Available at: https://doi.org/10.1007/s41660-020-00113-y.
    [Google Scholar]
  2. CDC, 2020. COVID-19. Available at: https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html. Accessed April 4, 2020.
    [Google Scholar]
  3. Wu J et al., 2020. Clinical characteristics of imported cases of COVID-19 in Jiangsu province: a multicenter descriptive study. Clin Infect Dis. Available at: https://doi.org/10.1093/cid/ciaa199.
    [Google Scholar]
  4. Zhao J et al., 2020. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. Available at: https://doi.org/10.1093/cid/ciaa344.
    [Google Scholar]
  5. Dong X, Cao Y‐Y, Lu X‐X, Zhang J-J, Du H, Yan Y-Q, Akdis CA, Gao Y-D, 2020. Eleven faces of coronavirus disease 2019. Allergy. Available at: https://doi.org/10.1111/all.14289.
    [Google Scholar]
  6. CDC, 2020. Coronavirus disease 2019 (COVID-19). Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-hospitalized-patients.html. Accessed April 16, 2020.
    [Google Scholar]
  7. Guo L et al., 2020. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis. Available at: https://doi.org/10.1093/cid/ciaa310.
    [Google Scholar]
  8. Lin Q, Zhu L, Ni Z, Meng H, You L, 2020. Duration of serum neutralizing antibodies for SARS-CoV-2: lessons from SARS-CoV infection. J Microbiol Immunol Infect. Available at: https://doi.org/10.1016/j.jmii.2020.03.015.
    [Google Scholar]
  9. Shen C et al., 2020. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA e204783. Available at: https://doi:10.1001/jama.2020.4783.
    [Google Scholar]
  10. Lipsitch M, 2020. Who is Immune to the Coronavirus? The New York times. Available at: https://www.nytimes.com/2020/04/13/opinion/coronavirus-immunity.html. Accessed April 15, 2020.
    [Google Scholar]
  11. Bao L et al., 2020. Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. bioRxiv. Available at: https://doi.org/10.1101/2020.03.13.990226.
    [Google Scholar]
  12. Chen C et al., 2020. SARS-CoV-2–positive sputum and feces after conversion of pharyngeal samples in patients with COVID-19. Ann Intern Med. Available at: https://doi.org/10.7326/M20-0991.
    [Google Scholar]
  13. Wu Y et al., 2020. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol. Available at: https://doi.org/10.1016/s2468-1253(20)30083-2.
    [Google Scholar]
  14. Metcalf CJE, Ferrari M, Graham AL, Grenfell BT, 2015. Understanding herd immunity. Trends Immunol 36: 753755.
    [Google Scholar]
  15. Yuan J, Kou S, Liang Y, Zeng J, Pan Y, Liu L, 2020. PCR assays turned positive in 25 discharged COVID-19 patients Clin Infect Dis. Available at: https://doi:10.1093/cid/ciaa398.
    [Google Scholar]
  16. Li Y, Yao L, Li J, Chen L, Song Y, Cai Z, Yang C, 2020. Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19. J Med Virol. Available at: https://doi.org/10.1002/jmv.25786.
    [Google Scholar]
  17. U.S. FDA, 2020. Approval of Cellex, Inc. qSARS-CoV-2 IgG/IgM Rapid Test. Available at: https://www.fda.gov/media/136622/download. Accessed April 4, 2020.
    [Google Scholar]
  18. U.S. FDA, 2020. Cellex qSARS-CoV-2 IgG/IgM Rapid Test. Available at: https://www.fda.gov/media/136625/download. Accessed April 4, 2020.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.20-0302
Loading
  • Received : 16 Apr 2020
  • Accepted : 20 Apr 2020
  • Published online : 23 Apr 2020
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error